Co-Authors
This is a "connection" page, showing publications co-authored by CHRISTOPHER J LOGOTHETIS and ASHISH KAMAT.
Connection Strength
0.297
-
A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int. 2024 Sep; 134(3):449-458.
Score: 0.061
-
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620.
Score: 0.058
-
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol. 2023 04; 6(2):228-232.
Score: 0.051
-
Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience. 2020 Jun 26; 23(6):101201.
Score: 0.046
-
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010 May 15; 16(10):2861-71.
Score: 0.023
-
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2729-34.
Score: 0.021
-
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A. 2008 Sep 30; 105(39):14987-92.
Score: 0.020
-
Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol. 2005 Dec; 174(6):2186-90.
Score: 0.017